Benzinga
Benzinga
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Benzinga
dimanche, octobre 25
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Addex Therapeutics Ltd
ADXN
NASDAQ
Liste de surveillance
Get Report
Trade with Public
Get Report
Trade with Public
$2.97
0.0779
2.69%
Dern. MÀJ: Oct 23, 9:18 AM
Get Report
Aperçu
Actualités
Prévisions de résultats
Événements
Objectifs de cours
Données financières
Sentiment
Comparer
Rapport sur les stocks
Addex Therapeutics Financials
Addex Therapeutics (ADXN) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
CORRECTION: Addex Therapeutics Q2 EPADS $(2.16) Up From $(2.90) YoY, Sales $12.650K Down From $44.031K YoY
Addex Therapeutics (NASDAQ:ADXN) reported quarterly losses of $(2.16) per share. This is a 25.52 percent increase over losses of $(2.90) per share from the same period last year. The company reported $12.650 thousand
Benzinga Newsdesk
Earnings Scheduled For September 28, 2026
Companies Reporting Before The Bell • Kandi Technologies Gr (NASDAQ:KNDI) is likely to report earnings for its first quarter. • Inventiva (NASDAQ:IVA) is expected to report quarterly loss at $0.20 per share on revenue
Benzinga Insights
Earnings Scheduled For June 25, 2026
Companies Reporting Before The Bell • TD Synnex (NYSE:SNX) is projected to report quarterly earnings at $4.10 per share on revenue of $16.79 billion. • Yiren Digital (NYSE:YRD) is estimated to report earnings for its
Benzinga Insights
PRO
Addex Therapeutics Q1 EPS $(1.53) Down From $(1.33) YoY, Sales $10.214K Down From $78.928K YoY
Addex Therapeutics (NASDAQ:ADXN) reported quarterly losses of $(1.53) per share. This is a 15.04 percent decrease over losses of $(1.33) per share from the same period last year. The company reported $10.214 thousand
Benzinga Newsdesk
PRO
Addex Therapeutics Reports Q1 2026 Net Loss Of CHF 1.71M Versus CHF 1.47M A Year Ago, Cash CHF 0.9M
Basic and diluted loss per share remained stable at CHF 0.01 per share for the three-month periods ended March 31, 2026 and 2025.
Benzinga Newsdesk
Earnings Scheduled For April 30, 2026
Benzinga Insights
